Comparative real-world outcomes of stage III melanoma patients treated with talimogene laherparepvec or interleukin 2

Reitmajer, Markus; Nanz, Lena; Mueller, Nina; Leiter, Ulrike; Amaral, Teresa; Aebischer, Valentin; Flatz, Lukas; Forschner, Andrea

dc.contributor.author	Reitmajer, Markus
dc.contributor.author	Nanz, Lena
dc.contributor.author	Amaral, Teresa
dc.contributor.author	Aebischer, Valentin
dc.contributor.author	Flatz, Lukas
dc.contributor.author	Müller, Nina
dc.contributor.author	Leiter-Stöppke, Ulrike
dc.contributor.author	Forschner, Andrea Lydia
dc.date.accessioned	2026-01-13T09:29:06Z
dc.date.available	2026-01-13T09:29:06Z
dc.date.issued	2025
dc.identifier.issn	1758-8340
dc.identifier.uri	http://hdl.handle.net/10900/173899
dc.language.iso	en	de_DE
dc.publisher	London : Sage Publications Ltd	de_DE
dc.relation.uri	http://dx.doi.org/10.1177/17588359251324035	de_DE
dc.subject.ddc	610	de_DE
dc.title	Comparative real-world outcomes of stage III melanoma patients treated with talimogene laherparepvec or interleukin 2	de_DE
dc.type	Article	de_DE
utue.quellen.id	20250630000000_02332
utue.personen.roh	Reitmajer, Markus
utue.personen.roh	Nanz, Lena
utue.personen.roh	Mueller, Nina
utue.personen.roh	Leiter, Ulrike
utue.personen.roh	Amaral, Teresa
utue.personen.roh	Aebischer, Valentin
utue.personen.roh	Flatz, Lukas
utue.personen.roh	Forschner, Andrea
dcterms.isPartOf.ZSTitelID	Therapeutic Advances in Medical Oncology	de_DE
dcterms.isPartOf.ZS-Issue	Article 17588359251324035	de_DE
dcterms.isPartOf.ZS-Volume	17	de_DE
utue.fakultaet	04 Medizinische Fakultät	de_DE